Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026

Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology firm focused on oral recombinant vaccines, announced its participation in the Global BioInnovation Forum on January 13, 2026. The event will showcase leaders in health innovation, emphasizing advancements in life sciences. Vaxart's CEO Steven Lo, along with Founder and Chief Scientific Officer Sean Tucker, Ph.D., and Chief Medical Officer James F. Cummings, M.D., will present at the forum, starting at 11:30 AM PT (2:30 PM ET). Interested parties can register and access the webcast via Vaxart's investor relations website, which will remain available for 30 days post-event.

Vaxart is pioneering a unique delivery platform that enables vaccines to be administered in pill form. This innovative approach has several advantages, including ease of storage and transportation without the need for refrigeration, and the mitigation of risks associated with needle-stick injuries. The company is strategically focusing on developing oral versions of established vaccines as well as new recombinant vaccines aimed to address various health challenges.

Current development programs at Vaxart include oral vaccines targeting diseases such as coronavirus, norovirus, and influenza. In addition, the company is exploring a therapeutic vaccine for human papillomavirus (HPV), marking its entry into immune-oncology indications. Vaxart has secured extensive patent coverage for its proprietary technology, which utilizes adenovirus and TLR3 agonists to enhance oral vaccination.

As Vaxart continues to innovate in the biotechnology space, their participation in forums like the Global BioInnovation Forum underscores their commitment to advancing the field of oral vaccination and health innovation.

As Vaxart, Inc. (OTCQX: VXRT) prepares for its participation in the Global BioInnovation Forum on January 13, 2026, investors should take note of the company's promising position in the biotechnology sector. Vaxart is at the forefront of developing oral recombinant vaccines, which utilize a novel delivery platform to provide a convenient and safer alternative to traditional vaccinations.

The global vaccination landscape has shifted dramatically, particularly following the COVID-19 pandemic, and the demand for innovative solutions continues to rise. Vaxart's technology allows for vaccines to be stored and transported without refrigeration, addressing key logistical challenges that have plagued vaccine distribution. This is particularly relevant in low- and middle-income countries, where access to cold chain storage remains a significant barrier.

Vaxart’s pipeline includes candidates for significant health threats such as coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV). The diversification across various diseases increases the company's market potential and appeal to investors. Notably, their HPV vaccine is a key component of their immune-oncology strategy, which may attract attention from investors interested in oncology therapeutics.

The participation of key executives such as Steven Lo, Sean Tucker, and James F. Cummings at the forum provides Vaxart an opportunity to highlight its advancements and strategic vision. This is a chance for the company to generate interest and possibly foster partnerships that could enhance its clinical development and commercialization efforts.

In summary, Vaxart’s innovative approach to oral vaccines and its diverse pipeline present a compelling investment opportunity. Investors should consider keeping a close watch on developments leading up to and following the Global BioInnovation Forum, as further insight into the company’s strategy could shape market sentiments and drive growth.